This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Oxurion (TBGN.F) Stock Overview

A biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. More details

TBGN.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($5M)

+ 3 more risks

TBGN.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW438,812 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

438,812 investors already sharing narratives

View all narratives

Oxurion NV Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oxurion
Historical stock prices
Current Share Price	€0.17
52 Week High	€2.00
52 Week Low	€0.17
Beta	0.38
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-91.54%
3 Year Change	-94.33%
5 Year Change	-97.28%
Change since IPO	-98.67%

Recent updates

Shareholder Returns

	TBGN.F	US Biotechs	US Market
7D	0%	-5.9%	-2.2%
1Y	-91.5%	34.6%	13.1%

Return vs Industry: TBGN.F underperformed the US Biotechs industry which returned -8.9% over the past year.

Return vs Market: TBGN.F underperformed the US Market which returned -20.7% over the past year.

Price Volatility

Is TBGN.F's price volatile compared to industry and market?
TBGN.F volatility
TBGN.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Stable Share Price: TBGN.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TBGN.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1991	42	Tom Graney	www.oxurion.com

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME.

Oxurion NV Fundamentals Summary

How do Oxurion's earnings and revenue compare to its market cap?
TBGN.F fundamental statistics
Market cap	US$5.66m
Earnings (TTM)	-US$30.82m
Revenue (TTM)	US$1.19m

4.7x

P/S Ratio

-0.2x

P/E Ratio

Is TBGN.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TBGN.F income statement (TTM)
Revenue	€1.13m
Cost of Revenue	€612.00k
Gross Profit	€516.00k
Other Expenses	€29.67m
Earnings	-€29.16m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Mar 24, 2023

Earnings per share (EPS)	-0.094
Gross Margin	45.74%
Net Profit Margin	-2,584.93%
Debt/Equity Ratio	-1,068.1%

How did TBGN.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/12/12 00:31
End of Day Share Price	2022/09/14 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oxurion NV is covered by 10 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Roderick Verhelst	Degroof Petercam
Divya Harikesh	Goldman Sachs
Steven Chesney	Goldman Sachs

Oxurion NVOTCPK:TBGN.F Stock Report